BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Enigma Diagnostics Announces New San Diego Office and Appointment of Joel Centeno, VP Regulatory & Quality


3/4/2010 8:58:58 AM

OXFORD, England and SAN DIEGO, March 4 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today the opening of its new Regional HQ office in San Diego, CA and the appointment of Joel Centeno as VP Regulatory & Quality.

Joel Centeno joins Enigma as VP Regulatory & Quality, US and will be responsible for obtaining appropriate regulatory approval for Enigma's rapid diagnostic instrument systems and products. Joel brings extensive executive experience in quality system design & implementation, new product development in molecular diagnostics and clinical trial expertise. Before joining the Enigma team, Joel served as Director, QA/RA at Hologic, Inc. where in addition to leading global quality and regulatory activities for the Molecular Diagnostic Division, he also obtained FDA approval on products including Cervista HPV and Inplex cystic fibrosis IVD tests. Joel received his B.S. in Materials Engineering and Metallurgy from the University of Florida in 1999.

About Enigma Diagnostics Limited

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of- care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.

For more information visit www.enigmadiagnostics.com.

Enigma Diagnostics Limited






Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES